DexCom and Rite Aid tumble while Abbott and AbbVie rise

Stocks that moved substantially or traded heavily Thursday:

Abbott Laboratories, up $1.49 to $53.64

Regulators approved Abbott's new blood glucose monitoring system.

Hain Celestial Group Inc., up 28 cents to $40.71

The tea and seasonings company ended a dispute with an investor by naming six new directors to its board.

McCormick & Co., up $5.20 to $101.65

The spice maker raised its annual forecasts after its quarterly results surpassed Wall Street estimates.

DexCom Inc., down $22.03 to $45.44

Investors see Abbott's blood glucose monitoring system, FreeStyle Libre Flash, as a major threat to DexCom's revenue.

Rite Aid Corp., down 25 cents to $2.03

The drug store chain's sales fell short of analyst estimates in the second quarter.

Pier 1 Imports Inc., down 30 cents to $4.20

The home decor company gave disappointing forecasts, partly because of the effects of Hurricanes Harvey and Irma.

AbbVie Inc., up $4.21 to $88.96

The drugmaker settled a patent dispute with Amgen, which won't sell a drug similar to AbbVie's Humira in the U.S. until 2023.

ConAgra Brands Inc., up 61 cents to $33.95

The maker of Chef Boyardee and other packaged foods had a better first quarter than analysts anticipated.